INTRODUCTION
Gastric cancer (GC) is one of the most common digestive system malignancies and has a high mortality rate, accounting for approximately 9% of cancer deaths worldwide [1] . Most patients with newly diagnosed GC have advanced stage disease that is not resectable [2, 3] . Moreover, patients who undergo complete tumor resection have a high risk of recurrence [4] . Chemotherapy has been widely adopted to prolong survival in patients with advanced GC. However, the overall survival rate of advanced GC remains unsatisfactory due to the development of multidrug resistance [5, 6] . Therefore, the mechanisms underlying chemotherapy resistance in GC are of major interest. Doxorubicin (DOX) is an anthracycline-based chemotherapeutic agent that has been used as the gold-standard therapy for advanced GC since 1980 [7] . However, DOX-based regimens are not currently recommended as a first-line chemotherapy strategy for GC due to frequent development of resistance and poor efficacy. The epithelial-to-mesenchymal transition (EMT) is a major mechanism associated with drug resistance. The EMT has been reported to promote cancer cell metastasis and resistance to chemotherapy [8, 9] . Recent studies demonstrated that the frequent acquisition of DOX resistance in cancer may be related to the EMT [10] [11] [12] [13] [14] . The protein alterations that occur during the EMT include a loss of epithelial markers, such as E-cadherin, and acquisition of mesenchymal markers, such as vimentin [15] . Several studies have investigated the relationship between the EMT and DOX-resistance in GC, and many factors involved in EMT mediated DOX-resistance have been discovered [16, 17] . However, the precise mechanisms by which the EMT is associated with DOXresistance have not yet been fully uncovered.
Dual specificity phosphatase 4 (DUSP4), a member of the DUSP family, is also known as MAPK phosphatase 2 (MKP2). DUSP4 plays an essential role in regulation of cell proliferation and differentiation via interacting with the MAPK signaling pathway [18] . However, contradictory roles have been reported for DUSP4 in cancer. As a negative regulator of the MAPK signaling pathway, DUSP4 may represent as a tumor suppressor gene. Downregulation of DUSP4 is associated with progression in several types of cancer, including colorectal cancer [19] , breast cancer [20] , pancreatic cancer [21] and diffuse large B cell lymphoma [22] . However, other studies indicate that overexpression of DUSP4 promotes cancer development and progression [23] [24] [25] . Interestingly, DUSP4 has been related to drug resistance in several cancers [26] [27] [28] [29] [30] . However, little is known about the role of DUSP4 in DOX resistance in GC.
In the present study, we aimed to explore the role of DUSP4 in DOX resistance in GC cell lines, uncover the associated mechanisms, and investigate the link between the EMT and doxorubicin resistance in gastric cancer.
RESULTS

GC cells expressing low levels of DUSP4 are more sensitive to DOX
To explore the effect of DUSP4 on the sensitivity of GC cells to DOX, the expression of DUSP4 was measured by Western blotting. KATOIII and MKN45 cells expressed high levels of DUSP4 compared to BGC and SGC7901 cells ( Figure 1A ). Next, we measured cell viability after 48 h DOX treatment using the CCK-8 assay.
All four GC cells exhibited dose-dependent reductions in cell viability in response to DOX ( Figure 1B , Table 1 ). However, DUSP4 high KATO III and MKN45 cells were more resistant to DOX than DUSP4 low BGC and SGC7901 cells. The EDU cell proliferation assay confirmed these results ( Figure 1C) 
DUSP4 promotes DOX resistance in GC cells
To further explore the relationship between DUSP4 and DOX resistance in GC cells, we employed a siRNA to knockdown DUSP4 and a plasmid to overexpress DUSP4. The efficacy of the siRNA and plasmid were confirmed Table 2 ). The EDU cell proliferation assay confirmed the results of the CCK-8 assay ( Figure 2F ) ( * P < 0.05, ** P < 0.01, *** P < 0.001). These data confirmed that DUSP4 significantly enhances the resistance of GC cells to DOX.
The EMT underlies DOX resistance in GC cells
As the EMT plays a role in chemoresistance in several solid tumors, we hypothesized the EMT may mediate DOX resistance in GC cells. To prove this hypothesis, we first investigated the expression of EMT marker proteins in the four GC cell lines by Western blotting. DOX-resistant DUSP4 high KATOIII and MKN45 cells expressed low levels of E-cadherin and high levels of vimentin, in contrast to DOX-sensitive DUSP4 the IC 50 of DOX for 48 h increased vimentin expression and decreased E-cadherin expression compared to the respective untreated cells ( Figure 3B ) ( ** P < 0.01, *** P < 0.001), indicating DOX can induce the EMT in GC cells.
Twist is an essential regulator of the EMT in cancer cells [31] . Therefore, we used a siRNA to knockdown Twist to inhibit the EMT. The CCK-8 assay revealed that knockdown of Twist increased the sensitivity of all four GC cell lines to DOX ( Figure 3C -3F, Table 3 ) and the EDU assay confirmed these results ( Figure 3G ) ( ** P < 0.01, *** P < 0.001), strongly suggesting that the EMT contributes to DOX resistance in GC cells.
Hypoxic culture can induce the EMT in cancer cell lines [32, 33] . To further confirm the role of the EMT in DOX resistance, we examined the viability and proliferation of GC cells cultured under hypoxic and normoxic conditions. Our results showed that DOX could reduce the viability of all four GC cell lines in a dosedependent manner; however, cells cultured under hypoxic conditions were more resistant to DOX than those cultured under normoxic conditions ( Figure 4A -4D, Table 4 ). The EDU assay confirmed hypoxia increased cell proliferation in a similar manner in DOX treated cells ( Figure 4E ) ( * P < 
Knockdown of DUSP4 inhibits the EMT in GC cells
Next, we investigated whether DUSP4 is involved in the EMT in GC cells. We transfected the DUSP4 siRNA or DUSP4 plasmid into the four GC cell lines, and quantified the expression of E-cadherin and vimentin. Knockdown of DUSP4 increased E-cadherin expression and reduced vimentin expression ( Figure 5A ). In contrast, overexpression of DUSP4 had the opposite effects ( Figure  5A ) ( * P < 0.05, ** P < 0.01, *** P < 0.001). These results indicated DUSP4 may regulate the EMT in GC cells. 
DUSP4 mediates DOX sensitivity in GC cells by regulating the EMT
Based on the results above, we inferred DUSP4 promotes DOX resistance in GC cells by regulating the EMT. To prove this, we examined the cell viability of cells overexpressing DUSP4, transfected with the Twist siRNA to inhibit the EMT and treated with DOX. Overexpression of DUSP4 did not further enhance DOX resistance when the EMT was blocked using the Twist siRNA ( Figure  6A -6D, Table 5 ). The EDU assay confirmed these results ( Figure 6E ).
As shown in Figure 4 , hypoxia could induce the EMT and enhance DOX resistance in GC cells. We investigated whether knockdown of DUSP4 could reverse the hypoxia-induced EMT and hypoxia-mediated DOX resistance. Cell viability and proliferation assays revealed that knockdown of DUSP4 could alleviate hypoxiamediated DOX resistance in GC cells ( Figure 7A -7E, Table 6 ) ( *** P < 0.001). These data demonstrate that DUSP4 enhances DOX resistance by regulating the EMT in GC cells.
DISCUSSION
Chemotherapy is the most effective treatment for advanced GC [3] . However, drug resistance limits the application of conventional DOX-based chemotherapy regimens in GC [34] . Thus, it is essential to explore the mediators and mechanisms of drug resistance in GC. In this study, we showed that overexpression of DUSP4 enhanced DOX resistance in GC cell lines by regulating the EMT. To the best of our knowledge, this is the first report of a relationship between DUSP4 and DOX resistance in GC. The dual specificity phosphatase DUSP4 specifically inactivates MAPK pathway kinases [18] . However, the role of DUSP4 in cancer remains controversial. Some studies have demonstrated DUSP4 is overexpressed and could promote progression in a number of cancers, including colorectal [19] and breast cancer [30, 35] . Conversely, other studies indicated DUSP4 is downregulated and inhibits tumor development in colorectal cancer [36] [37] [38] and breast cancer [25] . However, few studies have quantified DUSP4 expression in GC. One study reported that decreased DUSP4 expression was associated with sex, tumor size, depth of invasion and distant metastasis in human GC, and that overexpression of DUSP4 reduced GC cell viability and invasive potential and induced cell apoptosis and S phase cycle arrest [39] . However, little is known about the role of DUSP4 in chemoresistance in GC. The present study demonstrates DUSP4 promotes DOX resistance in GC, in agreement with findings in breast cancer [28] .
The EMT confers increased invasion and migration ability and is associated with drug resistance [8, 9] . EMTinduced stemness may represent one potential mechanism underlying EMT-mediated chemoresistance [40] . A previous study showed that long-term, incremental DOX treatment led to drug resistance and the EMT in SGC7901/ Dox cells [41] . Moreover, treatment with DOX for 48 h induced the EMT in human GC BGC-823 cells, and inhibition of β-catenin signaling suppressed the DOXinduced EMT and cell migration [16] . In agreement with these previous studies, we found the GC cell lines with a more mesenchymal phenotype, characterized by high vimentin and low E-cadherin expression, were more resistant to DOX. Furthermore, DOX induced vimentin and inhibited E-cadherin expression, indicting DOX induced the EMT in all four GC cell lines, and we confirmed the EMT mediates DOX resistance in GC.
Only two studies have reported a relationship between DUSP4 and the EMT. Boulding et al. demonstrated that DUSP1, DUSP4 and DUSP6 are induced during the EMT in breast cancer, and knockdown of DUSP4 could enhance breast cancer stem celldefine (CSC) formation [42] . Liu Y et al. found that overexpression of DUSP4 may promote the EMT in breast cancer, whereas knockdown of DUSP4 enhanced the sensitivity of chemotherapeutic agents in breast cancer cells [28] . Similarly, this study provides the first proof that DUSP4 can induce the EMT in GC and that blocking the EMT could reverse DUSP4-mediated DOX resistance in GC. In conclusion, our data demonstrates that high DUSP4 expression may promote the EMT in GC, whereas low DUSP4 expression may enhance DOX sensitivity. However, further research is required to determine the mechanism(s) by which down-regulation of DUSP4 inhibits the EMT and decreases the chemosensitivity of GC cells. Furthermore, these findings indicate that DUSP4 may have potential as a biomarker for monitoring DOX resistance in patients with GC and could represent a novel treatment target for GC.
MATERIALS AND METHODS
Cell culture
BGC-823, KATO III, SGC7901 and MKN45 human gastric cancer cells were purchased from the American Type Culture Collection Cell Biology Collection (ATCC, Manassas, VA, USA). BGC-823, SGC7901 and MKN45 cells were maintained in RPMI-1640 (Gibco, Grand Island, NY, USA); KATO III cells, in DMEM-High glucose (Gibco); all culture media were supplemented with 10% fetal bovine serum (FBS) and cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 . Hypoxic cultures were incubated at 37°C in a humidified atmosphere of 5% CO 2 and 1% O 2 . Doxorubicin was obtained from Sigma (St. Louis, MO, USA) and dissolved in ddH2O.
Cell transfection and RNA interference
GC cells were transfected with DUSP4 siRNA (100 nmol/L; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or Twist siRNA (100 nmol/L; Santa Cruz) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Non-specific negative control siRNA was purchased from GeneChem Co., Ltd. (Shanghai, China). Six hours after the cells were transfected, the media was replaced with fresh culture media. All assays were performed 48 h after transfection and repeated three times.
DUSP4 overexpressing plasmid
The DUSP4 plasmid was designed and constructed by GeneChem Co., Ltd. using the Trans-OE expression vector. The DUSP4 plasmid or control vector (1 μg each) were transfected into GC cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions; cells were assayed at 48 h post-transfection.
CCK-8 assay
Cell viability was assessed using the CCK-8 assay (Dojindo, Kumamoto, Japan). Approximately 5000 cells were seeded in 96-well plates in 100 μL medium. The cells were cultured in media containing 1% FBS for 24 h for synchronization, then different concentrations of DOX were added and the cells were incubated for 48 h. CCK-8 solution (10 μl) was added to each well, the cells were incubated for 2 h in the dark, then absorbance was measured at 450 nm using a MRX II microplate reader (Dynex, Chantilly, VA, USA). We used Prism 5 software (GraphPad, San Diego, CA, USA) to calculate the value of IC 50 .
Western blotting
Cells were homogenized in Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA), the supernatants were collected and total protein content was determined using the BCA assay (Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of protein (40 μg/lane) were separated on SDS-PAGE gels then transferred to 0.22 μm PVDF membranes (Millipore, Billerica, MA, USA). Membranes were blocked with 5% skimmed milk powder in PBST [0.1% Tween in PBS], incubated with E-cadherin, vimentin, β-actin or DUSP4 primary antibodies (1:1000; Abcam, Cambridge, MA, USA) overnight at 4°C, washed five times with PBST for 5 min, incubated with corresponding secondary antibodies (1:2000; abcam) for 1 h at room temperature, and target bands were visualized using the ECL kit (Millipore). 
EDU assay
Proliferation was determined using the Click-iTEdU Imaging Kit (Invitrogen) according to the manufacturer's protocol. Briefly, cells were incubated with their IC 50 of DOX for 24 h, fixed in 3.7% formaldehyde for 15 min at room temperature, and permeabilized in 0.5% Triton X-100 for 20 min at room temperature, washed twice with PBS containing 3% BSA, incubated with 0.5 mL of ClickiT ® reaction cocktail for 30 min in the dark, then nuclei were counterstained with 1 mL of 1 × Hoechst 33,342 (1:2000) for 30 min. The numbers of proliferative cells (EDU-positive) in three random fields of view per slide were counted under a fluorescence microscope (Olympus, Tokyo, Japan).
Statistical analysis
SPSS17.0 software was used for statistical analysis. Data are expressed as the mean ± SD of three independent experiments and two groups were compared using the two-tailed Student's t-test and one-way analysis of variance (ANOVA) was used to compare multiple groups. Statistical significance was accepted if P < 0.05.
